Novel approaches of glucose-lowering therapy in type 2 diabetes and chronic kidney disease
| Autor: | Shamkhalova Shamkhalovna Minara, Marina Vladimirovna Shestakova, Natalya Petrovna Trubitsyna, Anastasia Sergeevna Severina |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
business.industry Endocrinology Diabetes and Metabolism Insulin medicine.medical_treatment Type 2 Diabetes Mellitus Incretin Type 2 diabetes Hypoglycemia medicine.disease Gastroenterology chemistry.chemical_compound Endocrinology chemistry Internal medicine Diabetes mellitus medicine Glycated hemoglobin business Kidney disease |
| Zdroj: | Problems of Endocrinology. 61:36-43 |
| ISSN: | 2308-1430 0375-9660 |
| DOI: | 10.14341/probl201561636-43 |
| Popis: | Frequency of the diabetes mellitus (DM) and chronic kidney disease (CKD) steadily increases around the world. Compensation of a carbohydrate metabolism plays a key role in prevention of development and progressing of CKD in patients with DM, that was proved in the largest researches. However at later stages of CKD compensation of a carbohydrate metabolism is extremely complicated because of high risk of hypoglycemia due to decrease in a renal gluconeogenesis, insulin and anti-hyperglycemic agents cumulation, inadequate level of glycated hemoglobin due to nephrogenic anemia. Thus, great care and an individual approach in choosing and intensification of hypoglycemic therapy are required in patients with diabetes. Incretin drugs have taken a worthy place in the international and national guidelines for the treatment of patients with type 2 diabetes mellitus (DM2). Inhibitors of dipeptidyl peptidase-4 (DPP-4) showed a favorable efficacy and safety profile in patients with normal renal function and patients with CKD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|